EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing’s Disease

Martin Reincke, Tugce Apaydin, Mariam Kakashvili, Nathalie L Albert, Jun Thorsteinsdottir, Júnia R O L Schweizer, Marily Theodoropoulou, Katharina Schilbach, Friederike Völter

Endocrinology and Metabolism · 2026

DOI: 10.3803/enm.2025.2728 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, 2026. Verfasst von Martin Reincke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV, Endocrinology, Diabetes and Metabolism, Ludwig-Maximilians-Universität (LMU) University Hospital, LMU Munich, Mun…. Hauptthemen laut MEDLINE: Pituitary ACTH Hypersecretion, Positron-Emission Tomography, Molecular Imaging, Adenoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation, Else Kröner-Fresenius Stiftung in support of the German Cushing's Registry CUSTODES.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cushing’s disease is caused by corticotroph tumors of the pituitary gland, resulting in adrenocorticotropic hormone hypersecretion and cortisol excess. The majority of the tumors are microadenomas. Magnetic resonance imaging (MRI) imaging is able to detect up to 70% of the corticotroph tumors. In the remaining patients, no tumor is detectable on MRI or there are equivocal changes without a clear demarcation of a tumor. Hence, the cure rates following transsphenoidal pituitary surgery are far from being satisfactory, with around 60% to 90% short-term remission in expert centers. Positron emission tomography (PET) has recently emerged as a potent method for the localization of small corticotroph adenomas and corticotroph adenomas without demarcation on the MRI. This review analyzes the radiopharmaceuticals most commonly used in evaluating pituitary disorders and explores the potential utilization of new PET tracers for personalized management of patients with Cushing’s disease. Especially 11C-methionine and 18F-fluorethyltyrosine PET have recently been reported to be highly sensitive methods to detect MRI-undetectable corticotropinomas in 80% to 100% of patients. If confirmed in randomized controlled trials, PET imaging could be a major break-through towards targeted, individualized surgical therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary ACTH HypersecretionPositron-Emission TomographyMolecular ImagingAdenomaACTH-Secreting Pituitary AdenomaHumansRadiopharmaceuticalsMagnetic Resonance ImagingPituitary Neoplasms

Stichwörter der Autor:innen

Adrenocorticotropic hormoneCorticotroph adenomaCortisolFluorethyltyrosine-positron emission tomographyPituitary adenomaPituitary tumor

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Internal Medicine IV, Endocrinology, Diabetes and Metabolism, Ludwig-Maximilians-Universität (LMU) University Hospital, LMU Munich, Munich, Germany. martin.reincke@med.uni-muenchen.de.
  • Department of Internal Medicine IV, Endocrinology, Diabetes and Metabolism, Ludwig-Maximilians-Universität (LMU) University Hospital, LMU Munich, Munich, Germany.
  • Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey.
  • David Tvildiani Medical University, Tbilisi, Georgia.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • German Research Foundation
  • Else Kröner-Fresenius Stiftung in support of the German Cushing's Registry CUSTODES
  • Else Kröner-Fresenius Stiftung in support of the German Cushing’s Registry CUSTODES

Zitieren

APA

Reincke, M., Apaydin, T., Kakashvili, M., Albert, N. L., Thorsteinsdottir, J., Schweizer, J. R. O. L., Theodoropoulou, M., Schilbach, K., & Völter, F. (2026). New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing’s Disease. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2025.2728

Vancouver

Reincke M, Apaydin T, Kakashvili M, Albert NL, Thorsteinsdottir J, Schweizer JROL, et al. New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing’s Disease. Endocrinology and Metabolism. 2026. doi:10.3803/enm.2025.2728

BibTeX
@article{Reincke2026,
  author = {Reincke, Martin and Apaydin, Tugce and Kakashvili, Mariam and Albert, Nathalie L and Thorsteinsdottir, Jun and Schweizer, Júnia R O L and Theodoropoulou, Marily and Schilbach, Katharina and Völter, Friederike},
  title = {New Sparks and Spots: Molecular Imaging with Positron Emission Tomography Will Change Management of Cushing’s Disease},
  journal = {Endocrinology and Metabolism},
  year = {2026},
  doi = {10.3803/enm.2025.2728}
}
Kostenlos starten →